Copper(II) Complexes: A New Horizon in Cancer Chemotherapy

 Featuring Dr. Salah S. Massoud – University of Louisiana, United States

📍 Oral In-Person Presentation at the International Conference on Cancer Science andResearch
📅 November 17–19, 2025 | Village Hotel Changi, Singapore

Title: Copper(II) complexes as potent chemotherapeutic agents for anticancer therapy

---

Why Copper(II) Complexes?

Cancer continues to be one of the most critical health challenges of our time. According to the World Health Organization (WHO), cancer claimed nearly 10 million lives in 2022, and projections suggest this number may rise to 16.4 million by 2040. While platinum-based drugs such as cisplatin, carboplatin, and oxaliplatin revolutionized chemotherapy, their severe side effects—including nephrotoxicity, neurotoxicity, immune suppression, and drug resistance—have limited their long-term effectiveness.

In this context, Copper(II) complexes are emerging as powerful candidates for next-generation chemotherapy. Over the past two decades, research has revealed their high cytotoxicity, better pharmacological profiles, and selective action against cancer cells. Notably, binuclear pyridyl-phenoxido Cu(II) complexes demonstrated remarkable antiproliferative activity with a high selectivity index in ovarian (A2780) and breast cancer (MCF-7) cell lines. Dr. Massoud’s presentation will highlight how these complexes function, their mechanisms of action, and their potential to transform cancer therapy.

---

About the Speaker

Dr. Salah S. Massoud is a renowned Distinguished Professor at the University of Louisiana, USA, and Alexandria University, Egypt. He earned his Ph.D. in Bioinorganic and Inorganic Chemistry from Boston University, following his B.Sc. and M.Sc. from Alexandria University.

His scientific journey is remarkable—200+ peer-reviewed publications, 200+ invited lectures worldwide, and groundbreaking research contributions in copper-based anticancer drugs, DNA cleavage, ATP hydrolysis, molecular magnetism, and lanthanide fluorescence. Beyond his research, Dr. Massoud actively serves on editorial boards and as a guest editor for leading scientific journals, influencing the global scientific community.

---

Conference Information

Event: International Conference on Cancer Science and Research

📅 Dates: November 17–19, 2025

📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502

📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967

🔗 Stay connected: Facebook | X (Twitter)

🔗 Click here to Register | Submit Your Abstract

#CancerResearch #OncologyConference #CancerScience2025 #CopperComplexes #CancerTherapy #ChemotherapyResearch #OncologyInnovation #MedicalResearch

Cardiac Coherence: A New Approach to Oncology Medicine

We are delighted to feature Nabhan Linda, Clinical Psychologist from France Digital University, France, who will be delivering a Poster Virtual Presentation at the International Conference on Cancer Science and Research, scheduled for November 17–19, 2025, at the Village Hotel Changi, Singapore.

---

Abstract

In the oncology clinic, the issue of anguish, stress and anxiety is a very important part of treatment. These affects can also condition the outcome of treatment, as well as patients' experiences of their disease. Cancer has specific psychological repercussions compared with other illnesses that do not call so deeply on the subject's being. How can we deal with anxiety other than by taking medication? From patients who have never used anxiolytics or antidepressants to those who are wary of them, the powerlessness in the face of such intimate and intrinsic suffering is being felt. Indeed, anxiety is at the heart of the patient's history. Not everyone experiences anxiety in the same way, or for the same reasons. On the one hand, it is a question of identifying these types of feelings and then trying to understand the ins and outs of them. There's something quite special about psychological suffering: it can't be understood. In other words, there is an inability to share feelings with others that plunges the subject into this distress. Welcoming people with words is our first line of approach to this suffering, but how can we really act? This is where the relevance of cardiac coherence comes in.

Cardiac coherence is a method of refocusing the subject which has a dual effect on the nervous system by activating breathing, and which in turn has an impact on the psyche.

What was interesting to observe was that, in reality, once in a state of anxiety, the emergency having been declared, it is extremely difficult to act on these moments when the patient is in a state of total feeling and is only trying not to drown in his thoughts and feelings. Introducing cardiac coherence into the world of oncology makes it possible to provide a method of preparing for the onset of anxiety. It is very complicated to anticipate anxiety and sometimes impossible to detect its triggers, but training your mind and spirit to react to the micro-signs that herald an emotional catastrophe is essential, all the more so in oncology medicine where the body is bruised.

What we have observed is linked to the person's basic level of stress. Is there a mental invasion, a cognitive disorder or even a difficulty in concentrating on myself that prevents access to the full potential of this method? As well as praising this technique, which has proved its worth, it sometimes gives an indication of a person's emotional and psychic interiority. It is by working in combination with psychotherapy that real, effective care can be provided in an oncology medicine that aims to be closer to humanity.

---

Biography

Nabhan Linda is a clinical psychologist specialising in oncology. She has worked with a large number of psychiatric patients in hospital, then oncology patients in adult wards, before developing her private practice. A cardiac coherence practitioner and founder of the OncopsyHeart Mindcare collective, she continues to develop her practice and her knowledge through numerous articles on oncology medicine.

---

📅 Event Dates: November 17–19, 2025
📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502
🌐 Event Website: https://cancer.miconferences.com/
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
📱 WhatsApp: +1 (424) 377 0967

🔗 Follow us for updates:

• Facebook: Mathews Events
• X (Twitter): Cancer World Conference

# Cardiaccoherence #Oncology #anxiety #NervousSystem #psychotherapy #Cancer2025 #MedicalOncologyConferences #UpcomingOncologyConferences #CancerResearch

GPER-driven Crosstalk in Breast Cancer: Bridging Drug Resistance and Tumor Microenvironment Remodelling

We are honored to announce that Dr. Tenghua Yu, Associate Chief Physician and Deputy Director of the Breast Surgery Department at Jiangxi Cancer Hospital & Institute, China, will be delivering an Oral Virtual Presentation at the International Conference on Cancer Science and Research, scheduled for November 17–19, 2025, at Village Hotel Changi, Singapore.

Presentation Overview

Triple-negative breast cancer (TNBC) remains one of the most aggressive and challenging forms of breast cancer, marked by poor prognosis and limited treatment options. Dr. Yu’s research sheds new light on the role of G protein-coupled estrogen receptor (GPER) in regulating the tumor microenvironment, particularly its interaction with cancer-associated fibroblasts (CAFs).

His study reveals how estrogen-activated GPER in CAFs stimulates glutamine production through the upregulation of key metabolic enzymes (GLUL and LDHB). This glutamine is then secreted and absorbed by TNBC cells, fueling their growth, motility, and resistance to chemotherapy. By elucidating the GPER/cAMP/PKA/CREB signaling pathway and its impact on metabolic coupling, Dr. Yu identifies GPER as a critical mediator of tumor progression.

The findings emphasize that targeting the estrogen/GPER/glutamine axis could offer promising therapeutic strategies to overcome resistance and suppress TNBC progression. This work highlights the growing importance of metabolic interventions in cancer treatment.

About Dr. Tenghua Yu

Dr. Yu is a dedicated clinician and researcher specializing in breast cancer treatment and tumor microenvironment studies. He earned his PhD from Chongqing Medical University (2013–2016) and furthered his research training at the University of Chicago Medical Center, USA (2024–2025). With more than 30 peer-reviewed publications in esteemed journals such as Oncogene, Clinical and Translational Medicine, and Molecular Cell Endocrinology, Dr. Yu continues to make significant contributions to the field of oncology.

Conference Details

📅 Dates: November 17–19, 2025
📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502
🌐 Website: https://cancer.miconferences.com/
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967

Follow us for updates:
🔹 Facebook
🔹 X (Twitter)

#CancerConferences #Oncogene #TraditionalMedicine #CancerResearch #Oncology #Chemotherapy #Cancer2025 #OncologyConferences #GPER #TNBCcells

Extracellular vesicle pathways as regulators of tumor-vascular interactions in glioblastoma

🧠 Virtual Presentation Spotlight – Cancer Conference 2025

📅 November 17–19, 2025 | 📍 Village Hotel Changi, Singapore & Online
🌐 Event Website

---

We are delighted to welcome Prof. Janusz Rak, MD, PhD, McGill University, Canada, as a distinguished Oral Virtual Presenter at the Cancer Conference 2025. Prof. Rak is a world-leading expert in pediatric hematology/oncology, renowned for his pioneering research into how cancer cells communicate with their environment via extracellular vesicles (EVs).

Presentation Title:
Extracellular vesicle pathways as regulators of tumor-vascular interactionsin glioblastoma

Glioblastoma (GBM) remains one of the most aggressive and lethal brain tumors, resisting conventional therapies despite decades of study. Prof. Rak’s groundbreaking work sheds new light on the critical role of extracellular vesicles in orchestrating communication between glioma stem cells (GSCs) and the vascular system—driving processes like angiogenesis, vasectasia, and immune cell access to tumor tissue.

His team has uncovered that GSC subtypes secrete unique repertoires of EVs, influencing vascular growth patterns in GBM. Of particular interest is their discovery of a VEGF-independent blood vessel enlargement process—vasectasia—triggered by EV-mediated transfer of oncogenic EGFRvIII to endothelial cells, which resists standard angiogenesis inhibitors. Moreover, endothelial-derived EVs can reprogram proneural GSCs into more invasive, therapy-resistant mesenchymal phenotypes. These insights reveal new therapeutic possibilities, including combining vascular modulation with immunotherapy to improve treatment outcomes.

About the Speaker:
Prof. Janusz Rak is a Professor of Pediatrics and Jack Cole Chair in Pediatric Hematology/Oncology at McGill University. He directs the Centre for Applied Nanomedicine (CAN) and leads innovative projects on EV-based liquid biopsy approaches in pediatric cancer. He is also a Fellow of the Royal Society of Canada, recognized for his exceptional contributions to cancer biology.

---

📞 Contact Us
📧 Email: cancer@mathewsconference.com
📱 WhatsApp: +1 (424) 377 0967
📞 Phone: +1 (312) 462-4448

#Glioblastoma #BrainCancerResearch #CancerConference #LiquidBiopsy #OncologyResearch #VirtualConference #MedicalResearch #Cancer2025

Keynote Speaker Announcement – International Conference on Cancer Science and Research 2025

We are thrilled to announce that Dr. Henrique Manuel dos Santos Faneca from the University of Coimbra (CNC-UC), Portugal, will join us as a Virtual Keynote Speaker at the upcoming International Conference on CancerScience and Research, scheduled for November 17-19, 2025, at Village Hotel Changi, Singapore, with an online participation option.

Presentation Title: Targeted gene and drug delivery nanosystems tohepatocellular carcinoma

Dr. Faneca’s pioneering work focuses on developing innovative nanosystems for the targeted delivery of drugs and genetic material to liver cancer cells. These systems are designed to maximize therapeutic benefits while reducing side effects, representing a promising advancement in the fight against HCC.

Join us for this insightful keynote and connect with experts in cancer research from around the world.

🔗 Register Today: https://cancer.miconferences.com/register
🌐 Visit Website: https://cancer.miconferences.com/

📧 cancer@mathewsconference.com | 📞 +1 (312) 462-4448 | 📱 WhatsApp: +1 (424) 377 0967

#CancerScience2025 #HCCResearch #Nanomedicine #GeneTherapy #CancerTreatment #MedicalConference

Information Leakage in Clinical AI—Dr Julia Sidorova’s Hard Truths for Oncologists and Bioinformaticians

 

Are Your “High‑Accuracy” Models Built on Invisible Cracks?

Machine‑learning models that predict survival curves, tumor recurrence, or treatment response can look spectacular in a Jupyter notebook—right up until they meet real clinical data. The silent culprit? Information leakage: hidden shortcuts that slip illicit clues from the future or from duplicate patient records into the training set.

Dr Julia Sidorova (Research Scientist, Bioinformatics Platform, CIBER‑EHD, Spain) has made it her mission to reveal—and repair—those cracks. At Cancer 2025 she’ll dissect how leakage sneaks into pipelines, why it cripples external validation, and which safeguards every oncology data team should adopt.

---

What She’ll Cover on Stage

Leakage Type	Real‑World Example	Fix You’ll Learn
Temporal leakage	Future lab results “accidentally” present during training	Time‑aware splits, forward‑chaining validation
Patient‑overlap leakage	Multiple CT slices from the same patient split across folds	Grouped k‑fold, patient‑level indexing
Pretraining leakage	Public backbone pre‑exposed to pathology labels	Audit of pretraining datasets & feature ablation
Site/batch leakage	Model learns the scanner brand, not the tumor	ComBat batch correction, domain adversarial nets

Key takeaway: When Dr Sidorova removed leakage, deep nets in survival analysis “often under‑performed vanilla linear regression.” Let that sink in.

---

Meet Dr Julia Sidorova

• PhD, Universidad Pompeu Fabra (Barcelona)

• Research Scientist, Instituto Carlos III de Salud (Madrid)

• Editorial Board, Frontiers in Neurology (Biomarkers) & IJMS (SI: AI in Molecular Cancer)

• ２０＋ peer‑reviewed papers merging classical stats with deep learning to test what really works

---

Event Snapshot

Conference	International Conference on Cancer Science & Research (Cancer 2025)
Dates	17 – 19 November 2025
Format	Hybrid—Singapore onsite + fully interactive virtual platform

---

Why Attend?

• Bulletproof your ML pipelines before they hit the clinic

• Collect CPD credits and SCOPUS‑indexed proceedings

• Network with oncologists, bioinformaticians, and AI regulators in one forum

---

Register Now

Secure your seat or virtual pass → https://cancer.miconferences.com/register

Questions?
📧 cancer@mathewsconference.com | ☎ +1 312 462 4448 | 💬 WhatsApp https://wa.me/14243770967

---

Let’s build AI models that earn clinicians’ trust—starting with a leak‑tight foundation.

---

#InformationLeakage #ClinicalAI #OncologyData #SurvivalAnalysis #Bioinformatics #MachineLearning #Cancer2025 #SingaporeEvents #CancerResearch #ModelValidation #DeepLearning #HealthcareAI #HybridConference #SingaporeEvents #OncologyConferences #CancerEvents

Nanomedicine’s Next Frontier: Prof. Thomas J. Webster Headlines Cancer 2025

About the Keynote Speaker
With an h-index of 129 and more than 70 000 citations, Prof. Thomas J. Webster has spent three decades converting nanotechnology concepts into FDA-approved products—most notably nano-structured spinal implants now enhancing the lives of 30 000+ patients without a single recorded failure. The former president of the U.S. Society for Biomaterials, founder of a dozen med-tech start-ups (several acquired by Medtronic), and recent Nobel Prize nominee, Prof. Webster currently serves on the faculty at Brown University, Hebei University of Technology, and other institutions worldwide.

Keynote Preview
Anti-Cancer Nanomedicine in Humans: 30 000 Successful Cases and Counting

Prof. Webster will trace his journey from lab bench to operating room, revealing how nano-engineered surfaces outperform conventional implants—especially for bone-cancer patients, where failure rates can reach 60 %. Expect to learn:

• How nano topographies destroy cancer cells, bacteria and inflammation without drugs

• FDA MAUDE data validating zero failures across tens of thousands of patients

• The emerging era of 4D-printed, environmentally friendly, AI-guided nano-materials poised to slash healthcare costs and extend global life expectancy

Why This Session Matters

Conventional Challenge	Nano-enabled Solution Prof. Webster Will Showcase
5 – 10 % implant failure (up to 60 % in bone cancer)	Nano spinal implants with a perfect clinical track record
Rising drug resistance & cost	Drug-free cancer killing via nano surface physics
Reactive, one-size-fits-all healthcare	Predictive sensors and smart nano-materials tailored to each patient

Event Snapshot

• Conference: International Conference on Cancer Science & Research (Cancer 2025)

• Dates: 17 – 19 November 2025

• Format: Hybrid — Singapore and fully interactive online platform

• Accreditation: CPD credits available | DOI for conference proceedings

Secure Your Seat
Lock in an onsite pass or virtual ticket now → https://cancer.miconferences.com/register

Contact Us
✉ cancer@mathewsconference.com | ☎ +1 (312) 462-4448 | 💬 WhatsApp https://wa.me/14243770967

---

Join Prof. Webster and a global oncology community as we redefine cancer care through nanotechnology at Cancer 2025.

---

#Cancer2025 #Nanomedicine #Oncology #Biomaterials #NanoImplants #PrecisionMedicine #CPDCredits #CancerConferences #OncologyConferences #Anticancer